JP2020523348A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523348A5
JP2020523348A5 JP2019568372A JP2019568372A JP2020523348A5 JP 2020523348 A5 JP2020523348 A5 JP 2020523348A5 JP 2019568372 A JP2019568372 A JP 2019568372A JP 2019568372 A JP2019568372 A JP 2019568372A JP 2020523348 A5 JP2020523348 A5 JP 2020523348A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
cancer
salt according
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019568372A
Other languages
English (en)
Japanese (ja)
Other versions
JP6979595B2 (ja
JP2020523348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037221 external-priority patent/WO2018231910A1/en
Publication of JP2020523348A publication Critical patent/JP2020523348A/ja
Publication of JP2020523348A5 publication Critical patent/JP2020523348A5/ja
Application granted granted Critical
Publication of JP6979595B2 publication Critical patent/JP6979595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019568372A 2017-06-13 2018-06-13 プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 Active JP6979595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518855P 2017-06-13 2017-06-13
US62/518,855 2017-06-13
PCT/US2018/037221 WO2018231910A1 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2020523348A JP2020523348A (ja) 2020-08-06
JP2020523348A5 true JP2020523348A5 (https=) 2021-07-26
JP6979595B2 JP6979595B2 (ja) 2021-12-15

Family

ID=64562741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019568372A Active JP6979595B2 (ja) 2017-06-13 2018-06-13 プロテインキナーゼ阻害剤としてのアミノチアゾール化合物

Country Status (13)

Country Link
US (1) US10300061B2 (https=)
EP (1) EP3638237B1 (https=)
JP (1) JP6979595B2 (https=)
KR (1) KR102372288B1 (https=)
CN (1) CN110831596B (https=)
AU (1) AU2018284249B2 (https=)
CA (1) CA3064081C (https=)
ES (1) ES2949616T3 (https=)
MX (1) MX393992B (https=)
MY (1) MY201291A (https=)
TW (1) TWI667236B (https=)
WO (1) WO2018231910A1 (https=)
ZA (1) ZA202000107B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102797697B1 (ko) 2018-05-25 2025-04-22 에이2에이 파마수티칼스, 잉크. 신종 항암제 후보로서, 매우 강력한 tacc3 억제제
JP7681018B2 (ja) * 2019-11-14 2025-05-21 エーツーエー ファーマシューティカルズ インコーポレーテッド 抗がん剤としてtacc3を標的とするイソオキサゾール誘導体
EP4087574A4 (en) * 2020-03-06 2024-01-17 National Health Research Institutes PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES
US11299489B1 (en) 2020-11-19 2022-04-12 National Health Research Institutes Thiazole compounds as protein kinase inhibitors
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
EP4499625A4 (en) 2022-03-24 2026-03-18 A2A Pharmaceuticals Inc CANCER COMPOSITIONS AND TREATMENT METHODS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2503715A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
AU2006231929B2 (en) * 2005-04-04 2012-09-06 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
AU2006258101A1 (en) * 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
GB0610909D0 (en) * 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
EP2736904B1 (en) * 2011-07-27 2016-03-16 AB Science Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit)
WO2013143466A1 (zh) * 2012-03-27 2013-10-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases

Similar Documents

Publication Publication Date Title
JP2020523348A5 (https=)
JP2019511564A5 (https=)
JP6495868B2 (ja) キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
CN105163584B (zh) 用于治疗癌症的化合物
ES2779152T3 (es) Derivados de (2-(5-isoindolin-2-il)pirimidin-4-il)-amina como inhibidores de Rho-quinasa para tratar enfermedades autoinmunes
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
TWI594986B (zh) Antineoplastic agent effect enhancer
WO2020130125A1 (ja) 抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
ES2576497T3 (es) Compuesto de piperidina novedoso o sal del mismo
JP2019535746A5 (https=)
JP2020503299A5 (https=)
CA2519898A1 (en) Oral administration of cyclic protein tyrosine kinase inhibitors
JPWO2019191470A5 (https=)
RU2016130932A (ru) Производные хинолона как ингибиторы рецептора фактора роста фибробластов
WO2018147275A1 (ja) 腫瘍治療用医薬組成物
JP2020536971A5 (https=)
JP2005508953A5 (https=)
JP6883913B2 (ja) ヒストンデメチラーゼ阻害剤
RU2016137356A (ru) Соединение нафтиламида, способ его получения и применение
JP2020534300A5 (https=)
JPWO2021115426A5 (https=)
CA3130471A1 (en) Pan-raf kinase inhibitor and use thereof
JPWO2021007307A5 (https=)
JPWO2019213570A5 (https=)
TWI258481B (en) Hexacyclic compounds